

Edgar Filing: RadNet, Inc. - Form 10-Q

RadNet, Inc.
Form 10-Q
May 21, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2007

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 0-19019

RADNET, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

NEW YORK
(State or other jurisdiction of
incorporation or organization)

13-3326724
(I.R.S. Employer
Identification No.)

1510 COTNER AVENUE
LOS ANGELES, CALIFORNIA
(Address of Principal Executive Offices)

90025
(Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (310) 478-7808

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.
(Check one):

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No

Edgar Filing: RadNet, Inc. - Form 10-Q

The number of shares of the registrant's common stock outstanding on May 9, 2007, was 34,497,155 shares (excluding treasury shares).

1

Table of Contents

RADNET, INC.

INDEX

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Consolidated Balance Sheets at March 31, 2007 (unaudited) and December 31, 2006

Consolidated Statements of Operations (unaudited) for the Three Months ended March 31, 2007 and 2006

Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2007 and 2006

Notes to Consolidated Financial Statements

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 4. CONTROLS AND PROCEDURES

PART II - OTHER INFORMATION

ITEM 1 Legal proceeding

ITEM 1A. Risk Factors

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 6 Exhibits

SIGNATURES

INDEX TO EXHIBITS

2

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements

Edgar Filing: RadNet, Inc. - Form 10-Q

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)

March 31,
2007
(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$ 1,175
Accounts receivable, net	76,301
Unbilled receivables and other receivables	42
Due from affiliates	--
Receivable for income taxes	6,536
Other current assets	8,078

Total current assets	92,132
----------------------	--------

PROPERTY AND EQUIPMENT, NET

158,155

OTHER ASSETS

Accounts receivable, net	1,305
Goodwill	61,537
Other intangible assets	59,182
Deferred financing costs, net	8,957
Investment in joint ventures	9,957
Trade name and other	5,051

Total other assets	145,989
--------------------	---------

Total assets	\$ 396,276
--------------	------------

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

Cash disbursements in transit	\$ 687
Accounts payable and accrued expenses	50,544
Notes payable	3,016
Due to affiliates	517
Obligations under capital leases	5,887

Total current liabilities	60,651
---------------------------	--------

LONG-TERM LIABILITIES

Line of credit	--
Notes payable, net of current portion	360,000
Obligations under capital lease, net of current portion	12,965
Other non-current liabilities	11,039

Total long-term liabilities	384,004
-----------------------------	---------

COMMITMENTS AND CONTINGENCIES

MINORITY INTERESTS

1,050

STOCKHOLDERS' DEFICIT

Preferred stock - \$.0001 par value, 30,000,000 shares authorized, none issued	--
Common stock - \$.0001 par value, 200,000,000 shares authorized; 35,409,655 and 34,973,780 shares issued; 34,497,155 and 34,061,281 shares outstanding	
at March 31, 2007 and December 31, 2006, respectively	4
Paid-in-capital	148,678

Edgar Filing: RadNet, Inc. - Form 10-Q

Accumulated other comprehensive income	(751)
(Accumulated deficit)	(196,665)

	(48,734)
Less: Treasury stock - 912,500 shares at cost	(695)

Total stockholders' deficit	(49,429)

Total liabilities and stockholders' deficit	\$ 396,276
	=====

The accompanying notes are an integral part of these financial statements.

3

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS)

	THREE MONTHS ENDED MARCH 31,	
	2007	2006
	-----	-----
	(UNAUDITED)	
NET REVENUE	\$ 105,815	\$ 39,650
OPERATING EXPENSES		
Operating expenses	81,400	29,830
Depreciation and amortization	10,650	4,004
Provision for bad debts	7,553	1,475
Loss (gain) on sale of equipment	--	(14)
Severance costs	538	--
	-----	-----
Total operating expenses	100,141	35,295
INCOME FROM OPERATIONS	5,674	4,355
OTHER EXPENSES (INCOME)		
Interest expense	10,916	4,379
Loss on debt extinguishment, net	--	2,097
Other expense	--	822
	-----	-----
Total other expense	10,916	7,298
LOSS BEFORE INCOME TAXES, MINORITY INTERESTS AND EARNINGS FROM MINORITY INVESTMENTS	(5,242)	(2,943)
Provision for income taxes	(16)	--
Minority interest in (income) loss of subs	(115)	--
Earnings from joint ventures	995	--
	-----	-----
NET LOSS	\$ (4,378)	\$ (2,943)
	=====	=====
BASIC AND DILUTED NET LOSS PER SHARE	\$ (0.13)	\$ (0.14)
WEIGHTED AVERAGE SHARES OUTSTANDING	34,387	20,703

Edgar Filing: RadNet, Inc. - Form 10-Q

Basic and diluted

The accompanying notes are an integral part of these financial statements.

4

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)

	THREE MONTHS ENDED MARCH 31,	
	2007	2006
	(unaudited)	
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (4,378)	\$ (2,943)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Depreciation and amortization	10,650	4,004
Provision for bad debts and allowance adjustments	7,553	1,475
Minority interests in consolidated subsidiaries	115	--
Distributions to minority interests	(319)	--
Equity in earnings of joint ventures	(995)	--
Distributions from joint ventures	1,164	--
Deferred financing cost interest expense	469	--
Net loss (gain) on disposal of assets	--	(14)
Loss on extinguishment of debt	--	2,097
Accrued interest expense	138	1,280
Employee stock compensation	2,220	164
Deferred revenue from sale of building	--	(22)
Amortization of tenant improvements and other contracts	(2)	--
Changes in operating assets and liabilities:		
Accounts receivable	(14,122)	(2,078)
Unbilled receivables	466	82
Other current assets	(1,072)	(17)
Other assets	952	(551)
Accounts payable and accrued expenses	6,173	1,601
	9,012	5,078
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of imaging facilities	(540)	(238)
Purchase of property and equipment	(4,790)	(2,006)
Purchase of Radiologix	(244)	--
Purchase of covenant not to compete contract	(250)	--
Payments collected on notes receivable	111	--
	(5,713)	(2,244)
CASH FLOWS FROM FINANCING ACTIVITIES		
Cash disbursements in transit	(4,413)	(702)
Principal payments on notes and leases payable	(1,412)	(1,945)
Repayment of debt upon extinguishments	--	(141,243)
Proceeds from borrowings upon refinancing	--	146,468
Debt issue costs	--	(5,472)
Proceeds from borrowings on notes payable & revolving credit	100	60
Payments on line of credit	(22)	--
Proceeds from issuance of common stock	402	--
	(4,413)	(702)

Edgar Filing: RadNet, Inc. - Form 10-Q

Net cash provided (used) by financing activities	(5,345)	(2,834)
	-----	-----
NET INCREASE (DECREASE) IN CASH	(2,046)	--
CASH, BEGINNING OF PERIOD	3,221	2
	-----	-----
CASH, END OF PERIOD	\$ 1,175	\$ 2
	=====	=====
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid during the period for interest	\$ 9,515	\$ 3,936

The accompanying notes are an integral part of these financial statements.

5

RADNET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

We entered into capital leases for approximately \$4,195,000 and \$365,000 for the three months ended March 31, 2007 and 2006, respectively.

6

RADNET, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - NATURE OF BUSINESS AND BASIS OF PRESENTATION

RadNet, Inc. or RadNet (formerly Primedex Health Systems, Inc.), was incorporated on October 21, 1985. Since its acquisition of Radiologix on November 15, 2006, the Company operates a group of regional networks comprised of 132 diagnostic imaging facilities located in seven states with operations primarily in California, the Mid Atlantic, the Treasure Coast area of Florida,

Edgar Filing: RadNet, Inc. - Form 10-Q

Kansas and the Finger Lakes (Rochester) and Hudson Valley areas of New York, providing diagnostic imaging services including magnetic resonance imaging, or MRI, computed tomography, or CT, positron emission tomography, or PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray, and fluoroscopy. The Company's operations comprise a single segment for financial reporting purposes.

The results of operations of Radiologix and its wholly owned subsidiaries have been included in the consolidated financial statements from the date of acquisition. The consolidated financial statements also include the accounts of Radnet Management, Inc., or RadNet Management, and Beverly Radiology Medical Group III, or BRMG, which is a professional corporation, all collectively referred to as "us" or "we". The consolidated financial statements also include Radnet Sub, Inc., Radnet Management I, Inc., Radnet Management II, Inc., SoCal MR Site Management, Inc., and Diagnostic Imaging Services, Inc., or DIS, all wholly owned subsidiaries of RadNet Management.

The operations of BRMG are consolidated with us as a result of the contractual and operational relationship among, BRMG, Dr. Berger, our CEO, and us. We are considered to have a controlling financial interest in BRMG pursuant to the guidance in EITF 97-2. Medical services and supervision at most of our California imaging centers are provided through BRMG and through other independent physicians and physician groups. BRMG is consolidated with Pronet Imaging Medical Group, Inc. and Beverly Radiology Medical Group, both of which are 99%-owned by Dr. Berger. Radnet provides non-medical, technical and administrative services to BRMG for which they receive a management fee.

Radiologix, our wholly-owned subsidiary, contracts with radiology practices to provide professional services, including supervision and interpretation of diagnostic imaging procedures, in its diagnostic imaging centers. The radiology practices maintain full control over the provision of professional radiological services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth.

Radiologix enters into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, it provides management services and receives a fee based on the practice group's professional revenue, including revenue derived outside of its diagnostic imaging centers. Radiologix owns the diagnostic imaging assets and, therefore, receives 100% of the technical reimbursements associated with imaging procedures.

Radiologix has no financial controlling interest in the contracted radiology practices, as defined in Emerging Issues Task Force Issue 97-2 (EITF 97-2); accordingly, it does not consolidate the financial statements of those practices in its consolidated financial statements.

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position, results of operations and cash flows for the interim periods ended March 31, 2007 and 2006 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim consolidated financial statements should be read in conjunction with the consolidated financial

Edgar Filing: RadNet, Inc. - Form 10-Q

statements and related notes thereto contained in our Annual Report on Form 10-K for the year ended October 31, 2006 and our transition report on Form 10-K/T for the two months ended December 31, 2006.

Certain prior period amounts have been reclassified to conform with the current period presentation. These changes have no effect on net income.

7

LIQUIDITY AND CAPITAL RESOURCES

We had a working capital of \$31.5 million at March 31, 2007 compared to \$30.1 million at December 31, 2006, and had a net loss of \$4.4 million and \$2.9 million during the three months ended March 31, 2007 and 2006, respectively. We also had a stockholders' deficit of \$49.4 million at March 31, 2007 compared to a \$47.0 million at December 31, 2006.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require significant amounts of capital for the initial start-up and development expense of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment, and to service our existing debt and contractual obligations. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Our business strategy with regard to operations will focus on the following:

- o Maximizing performance at our existing facilities;
- o Focusing on profitable contracting;
- o Expanding MRI and CT applications
- o Optimizing operating efficiencies; and
- o Expanding our networks

Our ability to generate sufficient cash flow from operations to make payments on our debt and other contractual obligations will depend on our future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of our control, will affect our financial performance. Taking these factors into account, including our historical experience and our discussions with our lenders to date, although no assurance can be given, we believe that through implementing our strategic plans and continuing to restructure our financial obligations, we will obtain sufficient cash to satisfy our obligations as they become due in the next twelve months.

NOTE 2 - BUSINESS ACQUISITION

On November 15, 2006, we completed our acquisition of Radiologix, Inc as a stock purchase. Under the terms of the merger agreement, Radiologix shareholders received an aggregate consideration of 11,310,950 shares (or 22,621,900 shares before the one-for-two reverse stock split effected in late November 2006) of our common stock and \$42,950,000 in cash.

The total purchase price and the allocation of the estimated purchase price discussed below are preliminary and have not been finalized. The preliminary estimated total purchase price of the merger is as follows:

Edgar Filing: RadNet, Inc. - Form 10-Q

(IN THOUSANDS)

Value of stock given by RadNet to Radiologix*	\$ 39,400
Cash	42,950
Estimated transaction fees and expenses**	15,208
<hr/>	
Total purchase price	\$ 97,558
<hr/>	

(*) Calculated as 11,310,950 shares multiplied by \$3.48 (average closing price of \$1.74 from June 28, 2006 to July 13, 2006, adjusted for the one-for-two reverse stock split).

(**) Includes \$8,274,000 in assumed liabilities of Radiologix, including \$3,210,000 in merger and acquisition fees and \$5,064,000 in Radiologix bond prepayment penalties.

Under the purchase method of accounting, the total estimated purchase price as shown above is allocated to Radiologix's net tangible and intangible assets based on their estimated fair values as of the date of acquisition. The purchase price allocation is preliminary and has not been finalized because the valuation of the assets and liabilities has not been completed. The following table summarizes the preliminary purchase price allocation at the date of acquisition.

8

(IN THOUSANDS)

Current assets	\$115,094
Property and equipment, net	86,659
Identifiable intangible assets	61,000
Goodwill	38,074
Investments in joint ventures	9,482
Other assets	999
Current liabilities	(24,150)
Accrued restructuring charges	(314)
Contracts	(8,994)
Assumption of debt	(177,358)
Long-term liabilities	(1,725)
Minority interests in consolidated subsidiaries	(1,209)
<hr/>	
Total purchase price	\$ 97,558
<hr/>	

We have estimated the fair value of tangible assets acquired and liabilities assumed. Some of these estimates are subject to change, particularly those estimates relating to the valuation of property and equipment and identifiable intangible assets. The final allocation of the purchase price will be based upon the fair value of Radiologix's assets and liabilities as determined by an external valuation expert.

CASH, MARKETABLE SECURITIES, INVESTMENTS AND OTHER ASSETS: We valued cash, marketable securities, investments and other assets at their respective carrying amounts as we believe that these amounts approximate their current fair values.

IDENTIFIABLE INTANGIBLE ASSETS: We expect identifiable intangible assets acquired to include management service agreements and covenants not to

Edgar Filing: RadNet, Inc. - Form 10-Q

compete. Management service agreements represent the underlying relationships and agreements with certain professional radiology groups. Covenants not to compete are contracts entered into with certain former members of management of Radiologix on the date of acquisition.

Identifiable intangible assets consist of:

(IN THOUSANDS)	ESTIMATED FAIR VALUE	ESTIMATED AMORTIZATION PERIOD	ANNUAL AMORTIZATION
Management service agreements	\$ 57,880	25 years	\$ 2,315
Covenants not to compete	3,120	1 to 2 years	1,810

We have determined the preliminary fair value of intangible assets through limited discussions with Radiologix management and a review of certain transaction-related documents prepared by Radiologix management.

Estimated useful lives for the intangible assets were based on the average contract terms, which are greater than the amortization period that will be used for management contracts. Intangible assets are being amortized using the straight-line method, considering the pattern in which the economic benefits of the intangible assets are consumed.

GOODWILL: Approximately \$38,074,000 has been allocated to goodwill. This is a decrease of approximately \$434,000 from our estimate at December 31, 2006, and includes a \$750,000 increase to net accounts receivable, offset by \$244,000 of additional legal and consulting fees related to the merger as well as \$71,000 of revisions to our estimated valuation of income tax receivables of Radiologix. Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets. In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets" goodwill will not be amortized but instead will be tested for impairment at least annually. We perform this test annually on October 1. In the event that management determines that the value of goodwill has become impaired, we will incur an accounting charge for the amount of impairment during the fiscal quarter in which the determination is made, which would normally be the fourth quarter. Because this goodwill was established through a stock purchase, no amount is deductible for tax purposes.

OPERATING LEASES: We assumed certain operating leases for both equipment and facilities. All related historical deferred rent liabilities have been eliminated. The establishment of any assets or liabilities associated with the Company's assumption of these operating leases is contingent upon final analysis from our external valuation experts.

9

NOTE 3 - FACILITY OPENINGS

In March 2007, we acquired the assets and business of Rockville Open MRI for \$540,000 in cash and the assumption of a capital lease of \$1.1 million. The center provides MRI services. The center is 3,500 square feet with a monthly rental of approximately \$8,400 per month. Approximately \$365,000 of goodwill was recorded from this transaction.

NOTE 4 - ADOPTION OF RECENT ACCOUNTING STANDARDS AND PRONOUNCEMENTS

In July 2006, the FASB issued SFAS Interpretation No. 48, "Accounting

Edgar Filing: RadNet, Inc. - Form 10-Q

for Uncertainty in Income Taxes - an interpretation of SFAS Statement No. 109" ("FIN 48"), and effective January 1, 2007, we adopted FIN 48. FIN 48 applies to all "tax positions" accounted for under SFAS 109. FIN 48 refers to "tax positions" as positions taken in a previously filed tax return or positions expected to be taken in a future tax return which are reflected in measuring current or deferred income tax assets and liabilities reported in the financial statements. FIN 48 further clarifies a tax position to include, but not limited to, the following:

- o an allocation or a shift of income between taxing jurisdictions,
- o the characterization of income or a decision to exclude reporting taxable income in a tax return, or
- o a decision to classify a transaction, entity, or other position in a tax return as tax exempt.

FIN 48 clarifies that a tax benefit may be reflected in the financial statements only if it is "more likely than not" that a company will be able to sustain the tax return position, based on its technical merits. If a tax benefit meets this criterion, it should be measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. This is a change from current practice, whereby companies may recognize a tax benefit only if it is probable a tax position will be sustained.

FIN 48 also requires that we make qualitative and quantitative disclosures, including a discussion of reasonably possible changes that might occur in unrecognized tax benefits over the next 12 months; a description of open tax years by major jurisdictions and a roll-forward of all unrecognized tax benefits, presented as a reconciliation of the beginning and ending balances of the unrecognized tax benefits on an aggregated basis.

We are subject to tax audits in several tax jurisdictions within the U.S. and will remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. Tax audits by their very nature are often complex and can require several years to complete. Information relating to our tax examinations by jurisdiction is as follows:

- o Federal -- we are subject to U.S. federal tax examinations by tax authorities for the tax years ended 2003 to 2007
- o State -- we are subject to state tax examinations by tax authorities for the tax years ended 2002 to 2007

The adoption of FIN 48 did not have a material impact on our financial statements or disclosures. As of January 1, 2007 and March 31, 2007 we did not recognize any assets or liabilities for unrecognized tax benefits relative to uncertain tax positions. We do not currently anticipate that any significant increase or decrease to the gross unrecognized tax benefits will be recorded during the next 12 months. Any interest or penalties resulting from examinations will continue to be recognized as a component of the income tax provision however, since there are no unrecognized tax benefits as a result of tax positions taken, there are no accrued interest and penalties.

Additionally, the future utilization of the Company's net operating loss carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that may have occurred previously or that could occur in the future.

NOTE 5 - COMPREHENSIVE INCOME

Edgar Filing: RadNet, Inc. - Form 10-Q

The following table summarizes total comprehensive income for the applicable periods (in thousands):

	Three Months Ended March 31,	
	2007	2006
Net income	\$ (4,378)	\$ (2,943)
Change in unrealized loss on the fair value of cash flow hedging	(678)	--
	-----	-----
Total comprehensive income	\$ (5,056)	\$ (2,943)
	-----	-----

10

NOTE 6 - EARNINGS PER SHARE

Earnings per share are based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, and includes the effect of the one-for-two reverse stock split effective November 28, 2006, as follows (in thousands):

	THREE MONTHS ENDED	
	2007	2006
Net loss	\$ (4,378)	\$
BASIC EARNINGS (LOSS) PER SHARE		
Weighted average number of common shares outstanding during the year	34,387	--
	-----	-----
Basic earnings (loss) per share:		
Basic loss per share	\$ (0.13)	\$
	-----	-----
DILUTED EARNINGS (LOSS) PER SHARE		
Weighted average number of common shares outstanding during the year	34,387	--
	-----	-----
Add additional shares issuable upon exercise of stock options and warrants	--	--
	-----	-----
Weighted average number of common shares used in calculating diluted earnings per share	34,387	--
	-----	-----
Diluted earnings (loss) per share:		
Diluted loss per share	\$ (0.13)	\$
	-----	-----

For the three months ended March 31, 2007 and 2006, we excluded all options, warrants and convertible debentures in the calculation of diluted earnings per share because their effect would be antidilutive. However, these instruments could potentially dilute earnings per share in future years.

NOTE 7 - INVESTMENT IN JOINT VENTURES

We have eight unconsolidated joint ventures with ownership interests ranging from 22% to 50%. These joint ventures represent partnerships with

Edgar Filing: RadNet, Inc. - Form 10-Q

hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures are accounted for under the equity method. Total assets at March 31, 2007 include notes receivable from certain unconsolidated joint ventures aggregating \$725,000. Interest income related to these notes receivable was approximately \$20,000 for the three months ended March 31, 2007. We also received management service fees of \$943,000 for the three months ended March 31, 2007, in connection with operating the centers underlying these joint ventures.

The following table is a summary of key financial data for these joint ventures as of and for the three months ended March 31 2007 (in thousands):

Current assets	\$16,578
Noncurrent assets	12,995
Current liabilities	3,365
Noncurrent liabilities	811
Minority interest	9,957
Net revenue	14,709
Net income	3,206

NOTE 8 - STOCK BASED COMPENSATION

We have three long-term incentive stock option plans. The 1992 plan has not issued options since the inception of the 2000 plan and the 2000 plan has not issued options since the adoption of the 2006 plan. The 2006 plan reserves 1,000,000 shares of common stock. Options granted under the plan are intended to qualify as incentive stock options under existing tax regulations. In addition, we have issued non-qualified stock options from time to time in connection with acquisitions and for other purposes and have also issued stock under the plans. Employee stock options generally vest over three to five years and expire five to ten years from date of grant.

11

As of March 31, 2007, 255,000, or approximately 99%, of all the outstanding stock options are fully vested. No options were granted during the three months ended March 31, 2007.

We have issued warrants under various types of arrangements to employees, in conjunction with debt financing and in exchange for outside services. All warrants are issued with an exercise price equal to the fair market value of the underlying common stock on the date of issuance. The warrants expire from five to seven years from the date of grant. Warrants issued to employees can vest immediately or up to seven years. Vesting terms are determined by the board of directors at the date of issuance. We issued 850,000 warrants during the three months ended March 31, 2007. As of March 31, 2007, 4,160,667, or approximately 82%, of all the outstanding warrants are fully vested.

As of November 1, 2005, we adopted SFAS No. 123(R), "Share-Based Payment," applying the modified prospective method. This Statement requires all equity-based payments to employees, including grants of employee options, to be recognized in the consolidated statement of earnings based on the grant date fair value of the award. Under the modified prospective method, we are required to record equity-based compensation expense for all awards granted after the

Edgar Filing: RadNet, Inc. - Form 10-Q

date of adoption and for the unvested portion of previously granted awards outstanding as of the date of adoption. The fair values of all options were valued using a Black-Scholes model.

In anticipation of the adoption of SFAS No. 123(R), we did not modify the terms of any previously granted awards.

Mssrs. Linden, Hames and Stolper who hold the positions of Executive Vice President and General Counsel, Executive Vice President and Chief Operating Officer and Executive Vice President and Chief Financial Officer, respectively, were issued certain warrants in prior periods which fully vest upon the sooner of their respective multi-year vesting schedules or at such time as the 30 day average closing stock price of our shares in the public market in which it trades equals or exceeds \$6.00. For the 30 day trading period ended March 7, 2007, the average closing price exceeded \$6.00 per share. Accordingly, these warrants fully vested resulting in the full expensing of the remaining unamortized fair value of these warrants of \$1.7 million.

The compensation expense recognized for all equity-based awards is net of estimated forfeitures and is recognized over the awards' service period. In accordance with Staff Accounting Bulletin ("SAB") No. 107, we classified equity-based compensation within operating expenses with the same line item as the majority of the cash compensation paid to employees.

The following table illustrates the impact of equity-based compensation on reported amounts (in thousands):

	THREE MONTHS ENDED MARCH 31,			
	2007		2006	
	IMPACT OF EQUITY-BASED		IMPACT OF EQUITY-BASED	
	AS REPORTED	COMPENSATION	AS REPORTED	COMPENSATION
Income from operations	\$ 6,424	\$ (2,220)	\$ 4,355	\$ (2,220)
Net loss	\$ (3,628)	\$ (2,220)	\$ (2,943)	\$ (2,220)
Net basic and diluted earning per share	\$ (0.11)	\$ (0.07)	\$ (0.14)	\$ (0.07)

The following summarizes all of our option and warrant transactions for the three months ended March 31, 2007:

OUTSTANDING OPTIONS	SHARES	WEIGHTED AVERAGE EXERCISE PRICE PER COMMON SHARE	WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS)	AGGREGATE INTRINSIC VALUE
Balance, December 31, 2006	350,625	\$ 1.01		\$1,000,000
Granted	--	--		--
Exercised	(86,125)	0.85		--
Canceled or expired	(7,000)	--		--
Balance, March 31, 2007	257,500	\$ 1.00	3.32	\$1,000,000
Exercisable at March 31, 2007	255,000	\$ 1.00	3.29	\$1,000,000

Edgar Filing: RadNet, Inc. - Form 10-Q

OUTSTANDING WARRANTS	SHARES	WEIGHTED AVERAGE EXERCISE PRICE PER COMMON SHARE	WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS)
Balance, December 31, 2006	4,590,667	\$ 1.20	
Granted	850,000	4.92	
Exercised	350,000	0.94	
Canceled or expired			
Balance, March 31, 2007	5,090,667	\$ 2.14	3.64
Exercisable at March 31, 2007	4,160,667	\$ 1.84	2.87

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on March 31, 2007 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holder had all option holders exercised their options on March 31, 2007. Total intrinsic value of options and warrants exercised during the three months ended March 31, 2007 was approximately \$1.9 million. As of March 31, 2007, total unrecognized share-based compensation expense related to non-vested employee awards was approximately \$4.5 million, which is expected to be recognized over a weighted average period of approximately 3.7 years.

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The weighted-average grant date fair value of stock options and warrants was \$3.19 for the three months ended March 31, 2007 and \$0.41 for the three months ended March 31, 2006. The following is the weighted average of the data used to calculate the fair value:

	Risk-free Interest Rate	Expected Life	Expected Volatility	Expected Dividend Yield
March 31, 2007	4.66%	3.8 years	94.36%	
March 31, 2006	4.33%	4.8 years	92.21%	

We have determined the expected term assumption under the "Simplified Method" as defined in SAB 107. The expected stock price volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant with an equivalent remaining term. We have not paid dividends in the past and do not currently plan to pay any dividends in the near future.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

OF OPERATIONS

OVERVIEW

Since our acquisition of Radiologix on November 15, 2006, we operate a

Edgar Filing: RadNet, Inc. - Form 10-Q

group of regional networks comprised of 132 diagnostic imaging facilities located in seven states with operations primarily in California, the Mid Atlantic, the Treasure Coast area of Florida, Kansas and the Finger Lakes (Rochester) and Hudson Valley areas of New York., providing diagnostic imaging services including magnetic resonance imaging, or MRI, computed tomography, or CT, positron emission tomography, or PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray, and fluoroscopy. The Company's operations comprise a single segment for financial reporting purposes.

The results of operations of Radiologix and its wholly owned subsidiaries have been included in the consolidated financial statements from the date of acquisition. The consolidated financial statements also include the accounts of RadNet, Inc., Radnet Management, Inc., or Radnet Management, and Beverly Radiology Medical Group III, or BRMG, which is a professional corporation, all collectively referred to as "us" or "we". The consolidated financial statements also include Radnet Sub, Inc., Radnet Management I, Inc., Radnet Management II, Inc., SoCal MR Site Management, Inc., and Diagnostic Imaging Services, Inc., or DIS, all wholly owned subsidiaries of Radnet Management.

13

The operations of BRMG are consolidated with us as a result of the contractual and operational relationship among, BRMG, Dr. Berger, our CEO, and us. We are considered to have a controlling financial interest in BRMG pursuant to the guidance in EITF 97-2. Medical services and supervision at most of our California imaging centers are provided through BRMG and through other independent physicians and physician groups. BRMG is consolidated with Pronet Imaging Medical Group, Inc. and Beverly Radiology Medical Group, both of which are 99%-owned by Dr. Berger. Radnet provides non-medical, technical and administrative services to BRMG for which it receives a management fee.

Radiologix, our wholly-owned subsidiary, contracts with radiology practices to provide professional services, including supervision and interpretation of diagnostic imaging procedures' performed in its diagnostic imaging centers. The radiology practices maintain full control over the provision of professional radiological services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth.

Radiologix enters into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, it provides management services and receives a fee based on the practice group's professional revenue, including revenue derived outside of its diagnostic imaging centers. Radiologix owns the diagnostic imaging assets and, therefore, receives 100% of the technical reimbursements associated with imaging procedures

Radiologix has no financial controlling interest in the contracted radiology practices, as defined in Emerging Issues Task Force Issue 97-2 (EITF 97-2); accordingly, it does not consolidate the financial statements of those practices in its consolidated financial statements.

All of our facilities employ state-of-the-art equipment and technology in modern, patient-friendly settings. Many of our facilities within a particular region are interconnected and integrated through our advanced information technology system. Ninety-five of our facilities are multi-modality sites,

Edgar Filing: RadNet, Inc. - Form 10-Q

offering various combinations of magnetic resonance imaging, or MRI, computed tomography, or CT, positron emission tomography, or PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray and fluoroscopy. Thirty-seven of our facilities are single-modality sites, offering either X-ray or MRI. Consistent with our regional network strategy, we locate our single-modality facilities near multi-modality sites to help accommodate overflow in targeted demographic areas.

At our facilities, we provide all of the equipment as well as all non-medical operational, management, financial and administrative services necessary to provide diagnostic imaging services. We give our facility managers authority to run our facilities to meet the demands of local market conditions, while our corporate structure provides economies of scale, corporate training programs, standardized policies and procedures and sharing of best practices across our networks. Each of our facility managers is responsible for meeting our standards of patient service, managing relationships with local physicians and payors and maintaining profitability.

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities.

CRITICAL ACCOUNTING ESTIMATES

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements that were prepared in accordance with generally accepted accounting principles, or GAAP. Management makes estimates and assumptions when preparing financial statements. These estimates and assumptions affect various matters, including:

- o Our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements;
- o Our disclosure of contingent assets and liabilities at the dates of the financial statements; and
- o Our reported amounts of net revenue and expenses in our consolidated statements of operations during the reporting periods.

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management's control. As a result, actual amounts could materially differ from these estimates.

The Securities and Exchange Commission, or SEC, defines critical accounting estimates as those that are both most important to the portrayal of a company's financial condition and results of operations and require management's most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.

As of the period covered in this report, there have been no material changes to the critical accounting estimates we use, and have explained, in both our annual report on Form 10-K for the fiscal year ended October 31, 2006 and our transition report on Form 10-K/T for the two months ended December 31, 2006.

RESULTS OF OPERATIONS

Edgar Filing: RadNet, Inc. - Form 10-Q

The following table sets forth, for the periods indicated, the percentage that certain items in the statement of operations bears to net revenue.

	THREE MONTHS ENDED MARCH 31,	
	2007	2006
	----- (UNAUDITED) -----	
NET REVENUE	100%	100%
OPERATING EXPENSES		
Operating expenses	76.9%	75.2%
Depreciation and amortization	10.1%	10.1%
Provision for bad debts	7.1%	3.7%
Loss (gain) on sale of equipment	0.0%	0.0%
Severance costs	0.5%	0.0%
	-----	-----
Total operating expenses	94.6%	89.0%
INCOME FROM OPERATIONS	5.4%	11.0%
OTHER EXPENSES (INCOME)	0.0%	0.0%
Interest expense	10.3%	11.0%
Loss on debt extinguishment, net	0.0%	5.3%
Other income	0.0%	0.0%
Other expense	0.0%	2.1%
	-----	-----
Total other expense	10.3%	18.4%
LOSS BEFORE INCOME TAXES, MINORITY INTERESTS AND EARNINGS FROM MINORITY INVESTMENTS	-5.0%	-7.4%
Provision for income taxes	0.0%	0.0%
Minority interest in (income) loss of subs	-0.1%	0.0%
Earnings from minority investments	0.9%	0.0%
	-----	-----
NET LOSS	-4.1%	-7.4%
	=====	=====

THREE MONTHS ENDED MARCH 31, 2007 COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2006

NET REVENUE

Net revenue from continuing operations for the three months ended March 31, 2007 was \$105.8 million compared to \$39.7 million for the three months ended March 31, 2006, an increase of \$66.2 million, or 166.9%. Net revenue from the acquisition of Radiologix, effective November 15, 2006, was \$64.8 million for the three months ended March 31, 2007. Net revenue excluding Radiologix increased \$1.4 million for the three months ended March 31, 2007 when compared to the same period last year. This increase is net of the effects of reimbursement reductions experienced as a result of the DRA which became effective in January 2007

OPERATING EXPENSES

Edgar Filing: RadNet, Inc. - Form 10-Q

Operating expenses from continuing operations for the three months ended March 31, 2007 increased approximately \$51.6 million, or 172.9%, from \$29.8 million for the three months ended March 31, 2006 to \$81.4 million for the three months ended March 31, 2007. The following table sets forth our operating expenses for the three months ended March 31, 2007 and 2006 (in thousands):

15

Salaries and professional reading fees (excluding stock based compensation and severance)
Stock based compensation
Severance
Building and equipment rental
General administrative expenses (excluding NASDAQ one-time listing fee)
NASDAQ one-time listing fee

Total operating expenses

Depreciation and amortization
Provision for bad debt
Loss (gain) on sale of equipment, net
Severance costs

o SALARIES AND PROFESSIONAL READING FEES (EXCLUDING STOCK COMPENSATION AND SEVERANCE)

Salaries and professional reading fees increased \$25.6 million, or 137.4%, to \$44.2 million for the three months ended March 31, 2007 compared to \$18.6 million for the three months ended March 31, 2006. During the three months ended March 31, 2007, salaries and professional reading fees were \$23.7 million for Radiologix. Salaries excluding Radiologix increased \$1.9 million for the three months ended March 31, 2007 when compared to the same period last year.

STOCK BASED COMPENSATION

Stock compensation increased \$2.0 million to \$2.2 million for the three months ended March 31, 2007 compared to \$164,000 for the three months ended March 31, 2006. This increase is primarily due to \$1.7 million of additional stock based compensation expense recorded during the three months ended March 31, 2007 as a result of the acceleration of vesting of warrants.

Messrs. Linden, Hames and Stolper who hold the positions of Executive Vice President and General Counsel, Executive Vice President and Chief Operating Officer and Executive Vice President and Chief Financial Officer, respectively, were issued certain warrants in prior periods which fully vest upon the sooner of their respective multi-year vesting schedules or at such time as the 30 day average closing stock price of our shares in the public market in which it trades equals or exceeds \$6.00. For the 30 day trading period ended March 7, 2007, the average closing price exceeded \$6.00 per share. Accordingly, these warrants

Edgar Filing: RadNet, Inc. - Form 10-Q

fully vested resulting in the full expensing of the remaining unamortized fair value of these warrants of \$1.7 million.

SEVERANCE

During the three months ended March 31, 2007, we recorded severance costs of \$538,000 associated with the integration of Radiologix.

o BUILDING AND EQUIPMENT RENTAL

Building and equipment rental expenses increased \$7.6 million, or 363.5%, to \$9.7 million for the three months ended March 31, 2007 compared to \$2.1 million for the three months ended March 31, 2006. During the three months ended March 31, 2007, building and equipment rental expense was \$7.3 million for Radiologix. Building and equipment rental expenses excluding Radiologix increased \$336,000 for the three months ended March 31, 2007 when compared to the same period last year. The increase was due to normal consumer price index escalations built into the operating leases, and the increase in equipment rental was primarily due to the increased costs of renting mobile MRI equipment while repairs were being done at our Orange California facility.

o GENERAL AND ADMINISTRATIVE EXPENSES (EXCLUDING NASDAQ ONE-TIME LISTING FEE)

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature including

16

medical supplies and billing fees, which increase with volume and repairs and maintenance under our GE service agreement at 3.62% of net revenue for the three-month period. Overall, general and administrative expenses increased \$15.7 million, or 175.0%, for the three months ended March 31, 2007 compared to the previous period. During the three months ended March 31, 2007, general and administrative expenses were \$13.8 million for Radiologix. General and administrative expenses excluding Radiologix increased \$1.9 million for the three months ended March 31, 2006 when compared to the same period last year. The increase was primarily due to increased expenditures for accounting fees, costs related to repairs at our Orange California facility, and employee and marketing expenditures at year-end.

NASDAQ ONE-TIME LISTING FEE

During the three months ended March 31, 2007, we recorded \$120,000 for fees associated with listing our common stock with NASDAQ.

o DEPRECIATION AND AMORTIZATION

Depreciation and amortization increased \$6.6 million, or 166.0%, to \$10.6 million for the three months ended March 31, 2007 when compared to the same period last year. During the three months ended March 31, 2007, depreciation and amortization expense was \$6.1 million for Radiologix which includes \$1.0 million of amortization of intangible assets associated with the fair value of management service agreements

Edgar Filing: RadNet, Inc. - Form 10-Q

and covenants not to compete. Depreciation and amortization expense excluding Radiologix increased \$486,000 for the three months ended March 31, 2007 when compared to the same period last year primarily due to property and equipment additions.

o PROVISION FOR BAD DEBT

Provision for bad debt increased \$6.1 million, or 412.0%, to \$7.6 million, or 7.1% of net revenue, for the three months ended March 31, 2007 compared to \$1.5 million, or 3.8% of net revenue, for the three months ended March 31, 2006. During the three months ended March 31, 2007, the provision for bad debt expense was \$5.5 million, or 8.5% of net revenue, for Radiologix. Historically, Radiologix has experienced higher bad debt expense as compared to our business pre-acquisition due to the higher concentration of business associated with hospital payers in the markets that Radiologix serves and the poor collection percentages that are inherent with hospital business. Provision for bad debt expense excluding Radiologix increased \$568,000 for the three months ended March 31, 2007 when compared to the same period last year. The increase was primarily due to increased write-offs due to billing issues related to untimely filing, and incomplete or incorrect demographic information collected at the sites.

INTEREST EXPENSE

Interest expense for the three months ended March 31, 2007 increased approximately \$6.5 million, or 149.3%, from the same period in 2006. The increase was primarily due to the increased indebtedness of \$360.0 million upon the acquisition of Radiologix as well as the amortization of our deferred finance costs associated with this new financing which was \$469,000 for the three months ended March 31, 2007. Also related to our increase in interest expense is a \$138,000 fair value adjustment of certain interest rate swaps during the three months ended March 31, 2007.

LOSS ON DEBT EXTINGUISHMENTS, NET

For the three months ended March 31, 2006, we recognized a loss on extinguishment of debt of 2.9 million.

INCOME TAX EXPENSE

For the three months ended March 31, 2007, we recognized \$16,000 in income tax expense related to certain state tax obligations of Radiologix.

MINORITY INTEREST IN (INCOME) LOSS OF SUBSIDIARIES

For the three months ended March 31, 2007, we recognized \$115,000 in minority interest expense related to consolidated joint ventures of Radiologix.

17

EQUITY IN EARNINGS FROM UNCONSOLIDATED JOINT VENTURES

For the three months ended March 31, 2007, we recognized equity in earnings from unconsolidated joint ventures of \$995,000 including \$971,000 from investments of Radiologix and \$24,000 from an investment in a PET center in Palm Desert, California.

Edgar Filing: RadNet, Inc. - Form 10-Q

LIQUIDITY AND CAPITAL RESOURCES

On November 15, 2006, we entered into a \$405 million senior secured credit facility with GE Commercial Finance Healthcare Financial Services (the "November 2006 Credit Facility"). This facility was used to finance our acquisition of Radiologix, refinance existing indebtedness, pay transaction costs and expenses relating to our acquisition of Radiologix, and to provide financing for working capital needs post-acquisition. The facility consists of a revolving credit facility of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility has a term of five years, the term loan has a term of six years and the second lien term loan has a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the "base rate on corporate loans posted by at least 75% of the nation's largest 30 banks" or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each of the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. We may request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. The credit facility includes customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees.

As part of the financing, we swapped 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the close of the agreement. On April 11, 2006, effective April 28, 2006, we entered into an interest rate swap on \$73.0 million fixing the LIBOR rate of interest at 5.47% for a period of three years. This swap was made in conjunction with the \$161.0 million credit facility closed on March 9, 2006. In addition, on November 15, 2006, we entered into an interest rate swap on \$107.0 million fixing the LIBOR rate of interest at 5.02% for a period of three years, and on November 28, 2006, we entered into an interest rate swap on \$90.0 million fixing the LIBOR rate of interest at 5.03% for a period of three years. Previously, the interest rate on the above \$270.0 million portion of the credit facility was based upon a spread over LIBOR which floats with market conditions.

The Company documents its risk management strategy and hedge effectiveness at the inception of the hedge, and, unless the instrument qualifies for the short-cut method of hedge accounting, over the term of each hedging relationship. The Company's use of derivative financial instruments is limited to interest rate swaps, the purpose of which is to hedge the cash flows of variable-rate indebtedness. The Company does not hold or issue derivative financial instruments for speculative purposes. In accordance with Statement of Financial Accounting Standards No. 133, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e., change in fair value) is initially reported as a component of other comprehensive income in the Company's Consolidated Statement of Stockholders' Equity. The remaining gain or loss, if any, is recognized currently in earnings. Of the derivatives that were not designated as cash flow hedging instruments, we recorded an increase to interest expense of approximately \$138,000 for the three months ended March 31, 2007. The corresponding liability of \$848,000 is included in the other non-current liabilities in the consolidated balance sheet at March 31, 2007. This liability was \$710,000 at December 31, 2006.

We operate in a capital intensive, high fixed-cost industry that

Edgar Filing: RadNet, Inc. - Form 10-Q

requires significant amounts of capital to fund operations. In addition to operations, we require significant amounts of capital for the initial start-up and development expense of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment, and to service our existing debt and contractual obligations. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Our business strategy with regard to operations will focus on the following:

- o Maximizing performance at our existing facilities;
- o Focusing on profitable contracting;
- o Expanding MRI and CT applications
- o Optimizing operating efficiencies; and
- o Expanding our networks

18

Our ability to generate sufficient cash flow from operations to make payments on our debt and other contractual obligations will depend on our future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of our control, will affect our financial performance. Taking these factors into account, including our historical experience and our discussions with our lenders to date, although no assurance can be given, we believe that through implementing our strategic plans and continuing to restructure our financial obligations, we will obtain sufficient cash to satisfy our obligations as they become due in the next twelve months.

SOURCES AND USES OF CASH

Cash decreased during the three months ended March 31, 2007 to \$1.2 million from \$3.2 million at December 31, 2006.

Cash provided by operating activities for the three months ended March 31, 2007 was \$9.0 million compared to \$5.1 million for the same period in 2006.

Cash used by investing activities for the three months ended March 31, 2007 was \$5.7 million compared to cash used of \$2.2 million for the same period in 2006. For the three months ended March 31, 2007 and 2006, we purchased property and equipment for approximately \$4.8 million and \$2.0 million, respectively. During the three months ended March 31, 2007, we recorded the purchase of a covenant not to compete contract for \$250,000 which we recorded to other intangible assets on our consolidated balance sheet. Also, during the three months ended March 31, 2007, we paid cash of \$540,000 for the purchase of an additional imaging facility.

Cash used for financing activities for the three months ended March 31, 2007 was \$5.3 million compared to \$2.8 million for the same period in 2006. The primary use of cash during the three months ended March 31, 2007 was related to the increase in our disbursements in transit of \$4.4 million, payments on notes and capital leases payable of \$1.4 million, offset by \$402,000 of cash generated from the issuance of our common stock through the exercise of options and warrants.

RECENT ACCOUNTING PRONOUNCEMENTS

In February 2007, the FASB issued SFAS No. 159, THE FAIR VALUE OPTION

Edgar Filing: RadNet, Inc. - Form 10-Q

FOR FINANCIAL ASSETS AND FINANCIAL LIABILITIES, which permits entities to choose to measure many financial instruments and certain warranty and insurance contracts at fair value on a contract-by-contract basis. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007 (January 1, 2008 for calendar-year-end companies). Management has not determined the effect the adoption of this statement will have on its consolidated financial position or results of operations.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect, among other things, management's current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "believes," "anticipates," "plans," "intends," "will," "expects," "should" and similar words and expressions are intended to identify forward-looking statements. Except as required under the federal securities laws or by the rules and regulations of the SEC, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. The factors included in "Risks Relating to Our Business," among others, could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements.

Specific factors that might cause actual results to differ from our expectations, include, but are not limited to:

- o economic, competitive, demographic, business and other conditions in our markets;
- o a decline in patient referrals;
- o changes in the rates or methods of third-party reimbursement for diagnostic imaging services;
- o the enforceability or termination of our contracts with radiology practices;
- o the availability of additional capital to fund capital expenditure requirements;
- o burdensome lawsuits against our contracted radiology practices and us;
- o reduced operating margins due to our managed care contracts and capitated fee arrangements;
- o any failure on our part to comply with state and federal anti-kickback and anti-self-referral laws or any other applicable healthcare regulations;

19

- o our substantial indebtedness, debt service requirements and liquidity constraints;
- o the interruption of our operations in certain regions due to earthquake or other extraordinary events;
- o the recruitment and retention of technologists by us or by radiologists of our contracted radiology groups;
- o successful integration of Radiologix operations;

Edgar Filing: RadNet, Inc. - Form 10-Q

- o and other factors discussed in the "Risk Factors" section or elsewhere in this report.

All future written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report might not occur.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We sell our services exclusively in the United States and receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets.

A large portion of our interest expense is not sensitive to changes in the general level of interest in the United States because the majority of our indebtedness has interest rates that were fixed when we entered into the note payable or capital lease obligation. On November 15, 2006, we entered into a \$405 million senior secured credit facility with GE Commercial Finance Healthcare Financial Services. This facility was used to finance our acquisition of Radiologix, refinance existing indebtedness, pay transaction costs and expenses relating to our acquisition of Radiologix, and to provide financing for working capital needs post-acquisition. The facility consists of a revolving credit facility of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility has a term of five years, the term loan has a term of six years and the second lien term loan has a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the "base rate on corporate loans posted by at least 75% of the nation's largest 30 banks" or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. We may request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. The credit facility includes customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees.

As part of the financing, we swapped at least 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the close of the agreement. On April 11, 2006, effective April 28, 2006, we entered into an interest rate swap on \$73.0 million fixing the LIBOR rate of interest at 5.47% for a period of three years. This swap was made in conjunction with the \$161.0 million credit facility closed on March 9, 2006. In addition, on November 15, 2006, we entered into an interest rate swap on \$107.0 million fixing the LIBOR rate of interest at 5.02% for a period of three years, and on November 28, 2006, we entered into an interest rate swap on \$90.0 million fixing the LIBOR rate of interest at 5.03% for a period of three years. Previously, the interest rate on the above \$270.0 million portion of the credit facility was based upon a spread over LIBOR which floated with market conditions.

In addition, our credit facility, classified as a long-term liability on our financial statements, is interest expense sensitive to changes in the general level of interest because it is based upon the current prime rate plus a

Edgar Filing: RadNet, Inc. - Form 10-Q

factor.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are not effective in alerting them prior to the end of a reporting period to all material information required to be included in our periodic filings with the SEC because we identified the following material weakness in the design of internal control over financial reporting: We concluded that we had (i) insufficient processes to identify and resolve non-routine accounting matters, such as the identification of off-balance sheet transactions and (ii) insufficient personnel resources and technical accounting expertise within the accounting function to resolve the recording of non-typical cost-based investments in accordance with generally accepted accounting principles. The incorrect accounting for the foregoing was sufficient to lead management to conclude that a material weakness in the design of internal control over the accounting for non-routine transactions existed at March 31, 2007.

20

We determined to change the design of our internal controls over non-routine accounting matters by the identification of an outside resource at a recognized professional services company that we can consult with on non-routine transactions and the employment of qualified accounting personnel to deal with this issue together with the utilization of other senior corporate accounting staff, who are responsible for reviewing all non-routine matters and preparing formal reports on their conclusions, and conducting quarterly reviews and discussions of all non-routine accounting matters with our independent public accountants. We engaged MorganFranklin, a consulting firm with the requisite accounting expertise, to assist us, from time to time, in the evaluation and application of the appropriate accounting treatment, to provide support in the form of technical analysis related to accounting and financial reporting matters that may arise, and to provide management advice with respect to their preliminary conclusions regarding issues we wish to bring to their attention. To the extent our Chief Financial Officer identifies any non-routine accounting matters which require resolution, he will contact MorganFranklin and work closely with them, our audit committee and our auditors to resolve any issues. We are continuing to evaluate additional controls and procedures that we can implement and may add additional accounting personnel during fiscal 2007 to enhance our accounting processes and technical accounting resources. We do not anticipate that the cost of this remediation effort will be material to our financial statements. We believe that the engagement of MorganFranklin and use of their services should adequately address the identified weakness. With the acquisition of Radiologix we have added additional technical accounting staff from their organization which we believe will further reduce any material weakness.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.

Edgar Filing: RadNet, Inc. - Form 10-Q

PART II - OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

At March 31, 2006, the status of all current legal matters previously disclosed in Part 1, Item 3, of our Form 10-K/T for the two months ended December 31, 2006 is unchanged.

ITEM 1A RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A Risk Factors" in our Form 10-K for the year ended October 31, 2006 and our Form 10-K/T for the two months ended December 31, 2006, which could materially affect our business, financial condition, and results of operations. The risks described in our Forms 10-K and 10-K/T are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three months ended March 31, 2007, we sold the following securities pursuant to an exemption from registration provided under Section 4(2) of the Securities Act of 1933, as amended:

In January 2007, we issued to one of BRMG's radiologists in order to obtain his services, a five-year warrant exercisable at a price of \$4.79 per share, which was the public market closing price for our common stock on the transaction date, to purchase 500,000 shares of our common stock. In January 2007, we issued to one of our key employees a six-year warrant exercisable at a price of \$4.74 per share, which was the public market closing price for our common stock on the transaction date, to purchase 250,000 shares of our common stock.

In February 2007, we issued to each of our four independent directors, as annual compensation in connection with their agreements to serve as directors, five year warrants to purchase 25,000 shares exercisable at a price of \$5.99 per share, which was the public market price for our common stock on the transaction date.

ITEM 6 EXHIBITS

The list of exhibits filed as part of this report is incorporated by reference to the Index to Exhibits at the end of this report.

21

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RADNET, INC.

(Registrant)

Edgar Filing: RadNet, Inc. - Form 10-Q

Date: May 21, 2007 By: /s/ HOWARD G. BERGER, M.D.

Howard G. Berger, M.D.,
President, Chief Executive Officer and Director

Date: May 21, 2007 By: /s/ Mark D. Stolper

Mark D. Stolper, Chief Financial Officer
(Principal Accounting Officer)

22

INDEX TO EXHIBITS

EXHIBIT NUMBER -----	DESCRIPTION -----
31.1	Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
31.2	Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Howard G. Berger, M.D. *
32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Mark D. Stolper *

* Filed herewith.

23